Does probiotic add-on therapy improve depression?
Yes, modestly, in this small trial. Depressed patients who took a high-dose probiotic for 4 weeks on top of their usual treatment, and took most of their doses, had a larger drop in clinician-rated depression scores than those on placebo, both right after the 4 weeks and at the 8-week follow-up. At 8 weeks, 80% of the probiotics group had responded to treatment versus 48% of the placebo group, but that difference fell just short of statistical significance. The randomized trial, published in Translational Psychiatry, included 47 depressed patients who completed the intervention (21 probiotics, 26 placebo).
Probiotics are thought to work by increasing beneficial bacteria like Lactobacillus in the gut. These bacteria may produce compounds that signal to the brain through the gut-brain axis. In this trial, the rise in Lactobacillus went along with lower depression scores, but that does not prove it caused the improvement.
What the data show:
- Depression scores: Clinician-rated scores (HAM-D) fell significantly more with probiotics than placebo, but only among patients who took most of their doses
- Treatment response: At the 8-week follow-up, 80% of probiotics patients responded (a drop of more than 57% in depression score) compared to 48% with placebo (p = 0.06, not significant)
- Remission rates: 55% remission rate in probiotics group versus 40% in placebo group at the 8-week follow-up
- Self-rated depression: Patients’ own ratings (BDI) did not improve more with probiotics than placebo
- Gut microbiome: Probiotics maintained microbial diversity while placebo group showed reduced diversity, and probiotics increased Lactobacillus abundance which correlated with decreased depressive symptoms
- Brain changes: Putamen activation in response to neutral faces fell in the probiotics group, which may reflect improved emotional processing. A direct comparison with the placebo group was not significant
- Study scope: 47 patients completed the 4-week intervention (21 probiotics, 26 placebo) with 900 billion CFU/day of 8-strain probiotic formula
A randomized controlled trial published in Translational Psychiatry examined the clinical, gut microbial, and neural effects of probiotic add-on therapy in depressed patients, finding that probiotics eased depressive symptoms alongside changes in gut microbiota and brain activity, highlighting the role of the microbiota-gut-brain axis in depression treatment.
Dr. Kumar’s Take
This was the first trial in people with major depression to measure symptoms, gut bacteria, and brain imaging together. The bacteria in the gut do more than help with digestion. They signal to the brain and may influence mood. Here, the researchers did not just track depression scores. They also looked at changes in gut bacteria and brain activity to see how probiotics might work. The results are encouraging but small. The benefit showed up only in patients who took most of their doses, the response difference missed significance, and patients’ own ratings did not improve more than with placebo. I see this as a reason for larger trials, not as proof.
Study Snapshot
This randomized controlled trial assigned depressed patients to receive either probiotic supplements or placebo as add-on therapy to their existing antidepressant treatment. The study used a multi-strain probiotic formula and measured clinical depression outcomes, gut microbiome composition through stool analysis, and brain activity patterns using neuroimaging. The comprehensive approach allowed researchers to track how probiotic intervention affected the entire gut-brain axis system.
Results in Real Numbers
This randomized controlled trial included 60 depressed patients, with 47 completing the 4-week intervention (21 in probiotics group, 26 in placebo group), representing a dropout rate of 30% in the probiotics group and 13% in the placebo group. Patients received either a multi-strain probiotic supplement containing 900 billion CFU/day of 8 different bacterial strains or placebo, in addition to their standard antidepressant treatment. Among patients who took more than 65% of their doses, the probiotics group had a significantly larger drop in HAM-D scores than placebo from baseline to the end of the 4-week intervention (effect size d = 0.62), and a larger one from baseline to the 8-week follow-up (d = 0.95). In the full sample, the difference was not significant. Treatment response, defined as greater than 57% improvement in depression scores, occurred in 80% of patients in the probiotics group compared to 48% in the placebo group at the 8-week follow-up, a strong trend that fell short of significance (p = 0.06). The remission rate was 55% in the probiotics group versus 40% in the placebo group at the 8-week follow-up. Self-rated depression, anxiety, and gut symptoms improved over time in both groups, with no difference between them.
Gut microbiome analysis of 89 stool samples from the study revealed that probiotics maintained microbial diversity (measured by inverse Simpson index, Pielou’s evenness, and Shannon index) while the placebo group showed reduced diversity over time. The probiotics group showed a significant increase in Lactobacillus genus abundance after the intervention, which was the only significant time-by-group interaction for bacterial taxa. Importantly, the increase in Lactobacillus abundance was associated with decreased depressive symptoms as measured by both the Hamilton Depression Rating Scale and Beck Depression Inventory in the probiotics group. The probiotics also helped maintain healthy enterotype distribution, with the placebo group showing a loss of the Prevotella enterotype (associated with positive emotional well-being) at follow-up, while the probiotics group maintained this beneficial enterotype. Neuroimaging showed a significant decrease in putamen activation in response to neutral faces within the probiotics group after the 4-week intervention, with no change in the placebo group. A direct comparison between the two groups was not significant. The putamen had been overactive in depressed patients compared to healthy controls at baseline. The authors interpret the decrease as a shift toward seeing neutral faces as less negative, which would ease the negative bias typical of depression. Brain changes were not linked to changes in symptoms or gut bacteria.
Who Benefits Most
Patients with depression who have not achieved complete symptom relief with standard treatments may benefit most from probiotic add-on therapy. Individuals with gastrointestinal symptoms alongside their depression may be particularly good candidates, as they may have underlying gut microbiome imbalances contributing to their mental health symptoms.
People interested in integrative approaches that address both physical and mental health may find probiotic therapy appealing as an addition to existing treatments. Probiotics are generally considered low risk for most healthy adults.
Safety, Limits, and Caveats
This was a small trial of 60 patients, 30% of the probiotics group dropped out, and the clinical benefit was significant only in patients who took most of their doses. Individual responses to probiotic supplements can vary based on existing gut microbiome composition and other factors. The research used specific probiotic strains, and different formulations may produce different results.
The study noted that probiotic therapy worked as an add-on to existing antidepressant treatment rather than as a standalone therapy. Some individuals may not respond to probiotic intervention, and the optimal duration and dosing of probiotic therapy for depression remains to be established.
Practical Takeaways
- Consider probiotic supplements as a potential add-on therapy for depression, particularly if you haven’t achieved complete symptom relief with standard treatments
- Look for multi-strain probiotic formulations that have been studied in clinical trials for mental health applications
- Understand that probiotics work gradually and may take several weeks to produce noticeable benefits for mood and mental health
- Discuss probiotic therapy with healthcare providers, especially if you have underlying gastrointestinal conditions or take other medications
- Consider probiotics as part of a comprehensive approach that includes attention to overall gut health through diet and lifestyle
What This Means for Depression Treatment
This study supports the gut-brain axis as a possible target for depression treatment and adds to the case for testing microbiome-based therapies in larger trials. The findings encourage further research into psychobiotics and personalized approaches based on individual microbiome profiles.
The research also highlights the importance of considering the whole-body systems approach to mental health rather than focusing solely on brain-based interventions.
Related Studies and Research
- Episode 31: Depression Explained, The Biology Behind the Darkness
- Episode 32: Depression Recovery Roadmap: A Step-by-Step, Evidence-Based Plan
- SMILES Trial: Dietary Improvement for Depression
- Diet Interventions for Depression: Review and Recommendations
FAQs
How do probiotics affect depression?
This study suggests probiotics may influence depression through the gut-brain axis. Probiotics raised Lactobacillus levels, and that rise went along with lower depression scores. Brain activity also changed, but those changes were not linked to the gut or symptom changes.
Can probiotics replace antidepressant medications?
This research studied probiotics as add-on therapy to existing antidepressants, not as a replacement. Probiotics should be considered complementary to, not a substitute for, established treatments.
How long does it take for probiotics to help with depression?
While individual responses vary, this study measured benefits over several weeks of treatment, suggesting that probiotic effects on mood develop gradually as gut microbiome changes occur.
Bottom Line
In this small trial, probiotic add-on therapy lowered clinician-rated depression scores more than placebo in patients who took most of their doses, alongside changes in gut bacteria and brain activity. Larger trials are needed before the gut-brain axis can be called a proven treatment target.
